ArticleCancer prevention research (Philadelphia, Pa.)2011
Altered histology provides a positive clinical signal in the bronchial epithelium.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.Cancer · 2013Trial
- Randomized phase II trial of sulindac for lung cancer chemoprevention.Lung cancer (Amsterdam, Netherlands) · 2013Trial
- Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2013Trial
- Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.Frontiers in oncology · 2023Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
The history of lung cancer chemoprevention trials has been uniformly disappointing in that the large phase III studies showed no effect or harm in actively smoking participants, and smaller phase II studies have also been negative. In this issue of the journal (beginning on page 793), Keith and colleagues report their randomized, placebo-controlled trial of the oral prostacyclin analogue iloprost, the first trial to show an improvement in bronchial histology (i.e., regression), which occurred in former, but not current, smokers with sputum atypia. This Perspective discusses the strength of the clinical signal provided by this observation and its implications for further drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.